A five-year follow-up of untreated patients with chronic
lymphocytic leukaemia treated with ofatumumab and chlorambucil:
final analysis of the Complement 1 phase 3 trial

J 2020

A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial

OFFNER, F.; T. ROBAK; A. JANSSENS; K. G. BABU; J. KLOCZKO et al.

Základní údaje

Originální název

A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial

Autoři

OFFNER, F.; T. ROBAK; A. JANSSENS; K. G. BABU; J. KLOCZKO; S. GROSICKI; Jiří MAYER; P. PANAGIOTIDIS; A. SCHUH; A. PETTITT; M. MONTILLO; O. WERNER; G. VINCENT; S. KHANNA a P. HILLMEN

Vydání

British journal of haematology, England, Wiley-Blackwell, 2020, 0007-1048

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.998

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/20:00116537

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

ofatumumab; chlorambucil; Complement 1; anti-CD20 monoclonal antibodies; chronic lymphocytic leukaemia

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 9. 2020 13:58, Mgr. Tereza Miškechová

Anotace

V originále

The Complement 1 trial investigated the efficacy and safety of ofatumumab + chlorambucil with chlorambucil monotherapy in patients with previously untreated chronic lymphocytic leukaemia (CLL). On long-term follow-up in the chemoimmunotherapy arm vs. the chemotherapy arm there was an estimated 12% (not significant) and 39% risk reduction in overall survival and progression-free survival, respectively. A high rate (61%) of treatment with next-line therapies in both the treatment arms may dilute any potential OS difference and confound the interpretation of the OS results. Addition of ofatumumab to chlorambucil demonstrated clinical benefit and tolerability as a frontline treatment option in patients unfit for fludarabine-containing therapy, with no new safety concerns.

Citovat

OFFNER, F.; T. ROBAK; A. JANSSENS; K. G. BABU; J. KLOCZKO; S. GROSICKI; Jiří MAYER; P. PANAGIOTIDIS; A. SCHUH; A. PETTITT; M. MONTILLO; O. WERNER; G. VINCENT; S. KHANNA a P. HILLMEN. A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. British journal of haematology. England: Wiley-Blackwell, 2020, roč. 190, č. 5, s. 736-740. ISSN 0007-1048. Dostupné z: https://doi.org/10.1111/bjh.16625.

@article{1681898,
   author = {Offner, F. and Robak, T. and Janssens, A. and Babu, K. G. and Kloczko, J. and Grosicki, S. and Mayer, Jiří and Panagiotidis, P. and Schuh, A. and Pettitt, A. and Montillo, M. and Werner, O. and Vincent, G. and Khanna, S. and Hillmen, P.},
   article_location = {England},
   article_number = {5},
   doi = {https://doi.org/10.1111/bjh.16625},
   keywords = {ofatumumab; chlorambucil; Complement 1; anti-CD20 monoclonal antibodies; chronic lymphocytic leukaemia},
   language = {eng},
   issn = {0007-1048},
   journal = {British journal of haematology},
   title = {A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial},
   url = {https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16625},
   volume = {190},
   year = {2020}
}

TY  - JOUR
ID  - 1681898
AU  - Offner, F. - Robak, T. - Janssens, A. - Babu, K. G. - Kloczko, J. - Grosicki, S. - Mayer, Jiří - Panagiotidis, P. - Schuh, A. - Pettitt, A. - Montillo, M. - Werner, O. - Vincent, G. - Khanna, S. - Hillmen, P.
PY  - 2020
TI  - A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial
JF  - British journal of haematology
VL  - 190
IS  - 5
SP  - 736-740
EP  - 736-740
PB  - Wiley-Blackwell
SN  - 00071048
KW  - ofatumumab
KW  - chlorambucil
KW  - Complement 1
KW  - anti-CD20 monoclonal antibodies
KW  - chronic lymphocytic leukaemia
UR  - https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16625
L2  - https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16625
N2  - The Complement 1 trial investigated the efficacy and safety of ofatumumab + chlorambucil with chlorambucil monotherapy in patients with previously untreated chronic lymphocytic leukaemia (CLL). On long-term follow-up in the chemoimmunotherapy arm vs. the chemotherapy arm there was an estimated 12% (not significant) and 39% risk reduction in overall survival and progression-free survival, respectively. A high rate (61%) of treatment with next-line therapies in both the treatment arms may dilute any potential OS difference and confound the interpretation of the OS results. Addition of ofatumumab to chlorambucil demonstrated clinical benefit and tolerability as a frontline treatment option in patients unfit for fludarabine-containing therapy, with no new safety concerns.
ER  -

OFFNER, F.; T. ROBAK; A. JANSSENS; K. G. BABU; J. KLOCZKO; S. GROSICKI; Jiří MAYER; P. PANAGIOTIDIS; A. SCHUH; A. PETTITT; M. MONTILLO; O. WERNER; G. VINCENT; S. KHANNA a P. HILLMEN. A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. \textit{British journal of haematology}. England: Wiley-Blackwell, 2020, roč.~190, č.~5, s.~736-740. ISSN~0007-1048. Dostupné z: https://doi.org/10.1111/bjh.16625.

Přehled o publikaci